GDC-0834 / Gilead - LARVOL DELTA

AI-MedCraft: A Strategy-Driven AI Platform for Multi-Objective Molecular Design. (PubMed, J Chem Inf Model) - "In a structure-based benchmark on the solubility rescue of the BTK inhibitor GDC-0834, AI-MedCraft achieves broader Pareto-front coverage than the scalar-reward reinforcement learning framework REINVENT 4 under matched objectives and computational cost. In a second case study, AI-MedCraft redesigns Efavirenz to retain HIV-1 reverse transcriptase engagement while reducing predicted 5-HT2A off-target binding, demonstrating its use in multiconstraint molecular optimization."

Journal • Human Immunodeficiency Virus • Infectious Disease

Assessing the role of TR in PROTAC development for BTK (ACS-Fall 2025) - "This project explores how changes in residence time (tR) translate when inhibitors are converted into PROTACs and how this influences the ternary complex formation and initial degradation velocity, focusing on Fenebrutinib and GDC-0834. To isolate warhead effects, we will retain PTD-10's linker and E3 ligase ligand. We hypothesize that the tR ratio will be conserved, enhancing our understanding of tR's role in PROTAC function for selective protein degradation."

Targeted Protein Degradation

"Been busy week for 3D printing models, #Btk bound by GDC-0834 https://t.co/2Or6zyE4pj #Ibrutinib @abbvie @JNJNews @JNJInnovation" (,@caseysteffen)

Biosimilar